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Background.Cellularadhesionmolecules (CAMs),whicharenormallyassociatedwith leukocyte trafficking, havealsobeen shown toplay
an essential role in tumor metastasis to non-CNS sites. However, the role played by CAMs in brain metastasis is largely unexplored. It is
known that leukocyte recruitment to the brain is very atypical and thatmechanisms of disease in peripheral tissues cannot be extrapo-
lated to the brain. Here, we have established the spatiotemporal expression of 12 key CAMs in the initial phases of tumor seeding in 2
different models of brain metastasis.
Methods. BALB/c or SCID mice were injected intracardially (105 cells/100 mL phosphate-buffered saline with either 4T1-GFP or
MDA231BR-GFPcells, respectively (n¼ 4–6/group),andexpressionof theCAMswasdeterminedby immunohistochemistryand immuno-
fluorescence colocalisation.
Results. Endothelial expression of E-selectin, VCAM-1, ALCAM, ICAM-1, VLA-4, and b4 integrin was markedly increased early in tumor
seeding. At the same time, the natural ligands to these adhesion molecules were highly expressed on the metastatic tumor cells both
in vitro and in vivo. Twoof these ligands showedparticularly high tumor cell expression (ALCAMandVLA-4), and consequently their func-
tional role in tumorseedingwasdetermined.AntibodyneutralizationofeitherALCAMorVLA-4significantly reduced tumorseedingwithin
the brain (.60% decrease in tumor number/mm2 brain; P, .05–0.01).
Conclusions. These findings suggest that ALCAM/ALCAM and VLA-4/VCAM-1 interactions play an important functional role in the early
stages of metastasis seeding in the brain. Moreover, this work identifies a specific subset of ligand-receptor interactions that may
yield new therapeutic and diagnostic targets for brain metastasis.
Keywords: brain, cellular adhesion molecules, endothelium, metastasis, mouse, neutralizing antibody.
Brain metastasis is estimated to occur in 10%–30% of all cancer
patients and most commonly originates from one of 3 primary
cancers: lung (40%–50%), breast (15%–25%), and melanoma
(5%–20%).1 Importantly, the brain is the only site of tumor
relapse in 60% of lung cancer patients, 25% of breast cancer
patients, and 55% of melanoma patients2 and is a frequent site
of therapeutic failure. The process of brain metastasis depends on
the success of several steps including cancer cell dissociation
from the primary tumor, dissemination and survival within the cir-
culation, adhesion and subsequent penetration of the blood brain
barrier, and proliferation within the brain microenvironment. The
initial stages of brain metastasis are difficult to detect in vivo, and
this is one of the primary reasons for poor prognosis.3
Critically,ourunderstandingofmetastaticprogression inthebrain
remains incomplete. The distinct steps of tumor cell extravasation
and subsequent metastatic colonization are mediated by a variety
of receptor-ligand pairs on opposing cell type; therefore, interactions
of tumor cells with components of the brain microenvironment are
crucial determinants in their progression towards metastasis, dor-
mancy, or clearance.4 Central to these interactions is the expression
of cell adhesion molecules (CAMs), cell surface receptors, ligands,
and growth factors, which can influence both progression and
tumor phenotype as metastases develop.5 At the same time, in
vitro studies have indicated that functional activation of tumor cell
surface markers may promote metastasis through a combination
of altered adhesive andmigratory cell functions.6
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Previous work at other metastatic sites, such as lung and liver,
have suggested a role for several CAMs in tumor cell adhesion
and extravasation;4,7 however, little is known about their role in
brain metastasis. The primary reason for our poor understanding
of the role of CAMs in brain metastasis is the unique nature of the
brain microenvironment, which means that processes in other
organs cannot simply be extrapolated to the brain. For example,
vessels in bonemarrow and liver are fenestrated,8 while the endo-
thelial cells in thebrain exhibit special tight junctionsandare there-
fore largely impermeable to many molecules. Moreover, the
endothelial cells are closely surrounded by a double layer of basal
lamina, and astrocyte end-feet closely ensheath these layers,
forming the glial limitans. This blood brain barrier confers a signifi-
cant and unique challenge to extravasatingmetastatic cells that is
not present elsewhere in thebody. At the sametime, it hasbecome
clear that the inflammatory response of the brain is markedly dif-
ferent to that of systemic organs,9 and thus even the CAMprofile of
the brain endothelium cannot be considered to follow the pattern
seen in liver, lung, or bone. In vitro studiesofmetastatic tumorcells
have provided some information on tumor cell adhesion to brain
endothelial cells and subsequent transendothelial migration,10
but these are limited by their nature in vitro. At the same time, in
vivo studies, although scarce, have demonstrated thatmetastatic
extravasation into the brain takes significantly longer than it does
in other organs,11 supporting the concept that this process may
requiredifferentmechanismsto those involvedatothermetastatic
sites. Thus, the role of specific CAMs during metastatic tumor
seeding to the brain remains unclear.
The primary aim of this study, therefore, was to determine the
expression of 12 different CAMs/ligands in the early stages of
metastasis pathogenesis in the brain in vivo during initial seeding
to the brain. The 12 CAMs were chosen on the basis of previous
work at other metastatic sites, and/or their involvement in other
neurological diseases. Expression of the same molecules was
also assessed on the metastatic tumor cells themselves both in
vivo and in vitro. Subsequently, we sought to determine whether
2of theCAMsthatwere found tobeupregulatedearlyon the endo-
thelium (ALCAM and VCAM-1) were functionally involved in the
initial steps of metastasis seeding to the brain.
Materials and Methods
In Vivo Models
As a primary model system, the metastatic murine mammary carcinoma
4T1-GFP cell line was used.12 Female BALB/c mice, 7–8 weeks old, were
anesthetized with 2%–3% isoflurane in oxygen and injected intracardially
into the left ventricle under ultrasound guidance (VEVO 770, Visualsonics)
with 1×105 primary 4T1-GFP cells in 100 mL phosphate-buffered saline
(PBS). Those CAMs showing significant levels of expression at day 10 and
colocalization with endothelial cell markers were further assessed at an
earlier timepoint (day5) in order toevaluate their role in theearlyarrest/ex-
travasation stage of metastasis (n¼ 4 per time point).
Asasecondmodel, a subcloneofametastatic humanbreast carcinoma
that preferentially metastasizes to the brain,13 MDA231BR-GFP (a kind gift
of Dr Patricia Steeg, National Cancer Institute, USA) was used. Female
SCID mice, 7–8 weeks old, were anesthetized as above and injected intra-
cardially with 1×105 MDA231BR-GFP cells in 100 mL PBS (n¼ 4). A later
time point was chosen for investigation, as previous experiments have
shown that this is a slower-growing tumor cell line; by day 21, the colonies
were of a similar size to those seen at day 10 in the 4T1-GFP model.14 All
experiments were approved by the UK Home Office.
Immunohistochemistry
Expression was assessed for the following adhesion molecules and ligands:
vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion
molecule-1 (ICAM-1), activated leukocyte cellular adhesion molecule
(ALCAM), E-selectin, P-selectin, L-selectin, P-selectin glycoprotein ligand-1
(PSGL-1), integrin a4 (subunit of the integrin VLA-4), very late antigen 4
(VLA-4 or integrin a4b1), integrin b4, lymphocyte function-associated
antigen-1 (LFA-1 or integrin aLb2 or CD11a/CD18), and vascular apoptosis-in-
ducing protein-1 (VAP-1).
All animalswere transcardially perfusion-fixedunder terminal anesthe-
siawith0.9%heparinizedsaline followedby200 mLofperiodate lysinepar-
aformaldehyde (PLP) containing only 0.025%glutaraldehyde (PLPlight). The
brains were postfixed, cryoprotected, embedded, and frozen in isopentane
at 2408C. For immunohistochemical detection of the 12 proteins, 10 mm
sections were collected onto gelatinized slides, washed in PBS (Thermo
Fisher Scientific), and quenched using 1% hydrogen peroxide (Sigma
Aldrich) in methanol. Slides were rewashed in PBS, placed in a Shandon
Sequenza staining clip (Thermo Fisher Scientific), and washed again. Sec-
tionswere blocked using 10%normal rabbit, goat or horse serum (depend-
ing on the antibody studied) (NRS/NGS/NHS; Vector Laboratories) in
Dulbecco’s PBS (Invitrogen). Slides were then incubated for 16 hours with
the appropriate primary antibody (see Primary Antibodies section) in PBS
containing 1% NRS or NGS or NHS and 0.05% Tween at 48C. For all of the
12 CAMs analyzed, negative control experiments (no primary antibody)
were included to verify specific immunostaining of CAMs; no immunoreac-
tive stainingwasevident in thesenegative controls. After rinsing inPBS, sec-
tions were incubated for 1 hour with the appropriate secondary antibody
(see Secondary Antibodies section). Slides were washed and then incu-
bated in Vectorelite ABC kit (1:1:100; Vector Laboratories) for 45 minutes.
The peroxidase was visualized using 3, 3′-diaminobenzidine (DAB; Sigma
Aldrich). Sections were counterstained with cresyl violet (Sigma Aldrich).
Finally, sections were mounted and coverslipped using DPX mounting
solution (Thermo Fisher Scientific).
All sections were counterstained with cresyl violet, under which condi-
tionsthetumorboundarywas readilydelineated.TodetermineCAMexpres-
sion levels, it was necessary to account for variations in DAB background
staining (brown). To this end, multiple pictures at . x200 magnification
(white balance corrected) were taken from regions outside the tumor per-
iphery and used as reference images to establish the basal level of DAB
stainingwithin individual sections. ExpressionofCAMswasconsideredposi-
tive only where DAB immunoreactivity was above that seen in background
reference images and was clearly cell-specific (Supplementary data,
Table S1).
To assess areas of individualmolecule expression, photomicrographs of
eachbrain sectionwereobtainedusingaNikonE800microscopecoupled to
aRoHScamera. Imageswere analyzedusingQcapture Pro software (Qima-
ging) and Adobe Photoshop CS4 (Adobe Systems Incorporated). Areas of
expression, as a percentage of total tumor area, were quantified for each
marker on ≥ 5 sections per animal.
Immunofluorescence
Immunofluorescent colocalization of each biomarker with endothelial
cells, microglia, astrocytes, or tumor cells was determined using either
fluorescent tyramide signal amplification (TSA, PerkinElmer) or secondary
antibodies attached to different dyes (AMCA or Cy3). Similarly, expression
of each biomarker on resting and stimulated tumor cells was evaluated
using Cy3 dye.
Sections were quenched with 1% hydrogen peroxide in PBS, streptavi-
din- and biotin-blocked (SP-2002; Vector Laboratories) and then incubated
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with Tris-NaCl blocking buffer (TNB, PerkinElmer). Sections were subse-
quently incubated for 16 hours at 48C with the appropriate primary anti-
body (see Primary Antibodies section), rinsed with PBS, and incubated
with the appropriate secondary antibody (see Secondary Antibodies
section) in TNB for 30 minutes. Sections were then washed with PBS, incu-
bated with streptavidin-HRP (1:200; PerkinElmer) in TNB for 30 minutes,
washed, and incubated for 8 minutes in the dark with TSA-biotin (1:100;
PerkinElmer) in amplification buffer (PerkinElmer). Slides were washed
and incubated with a streptavidin-Cy3 fluorophore (1:200; Invitrogen) for
30 minutes.Todetect theotherfluorophore, theAMCA-conjugatedsecond-
ary antibody was added at the same time as streptavidin-Cy3. Slides were
coverslipped using Vectashield mounting medium (Vector Laboratories).
Imageswereacquiredusingan invertedconfocalmicroscope(LSM-710;
Carl Zeiss Microimaging) or Leica DM IRBE (Leica) attached to a camera
(Hamamatsu, Japan), and analyzed using either Zen (Carl Zeiss) software
or Simple PCI (Hamamatsu) software, respectively. Detection ranges were
set to eliminate crosstalk between fluorophores: 409–485 nm for AMCA,
494–553 nm for GFP, and 564–712 nm for Cy3.
In Vitro Study
CAM expression was also analyzed on both cell lines (4T1-GFP and
MDA231BR-GFP) invitro. Cellswere seededonto96-well platesandcultured
for 48 hours in Dulbecco’s Modified Eagle’s Medium (DMEM)medium (10%
fetal bovine serum, 1%glutamine). For the stimulated conditions, 4T1-GFP
cells were incubated with either 55% mouse (BALB/c) plasma in DMEM or
50 ng/mL mouse CXCL12 (SDF1a; PeproTech). MDA231BR-GFP cells were
incubated with 55% human plasma in DMEM or 50 ng/mL human
CXCL12 (SDF1a (PeproTech). Cells were exposed to the stimulus for
6 hours. CXCL12 was chosen because its receptor, CXCR4, is present in
both cell lines and is highly activated on several metastatic tumor cells
that actively metastasize to the brain.5,15
Following exposure to the different stimuli, cells were washed 3 times
with PBS and fixed for 10 minutes with 4% PFA. Subsequently, cells were
washed with PBS/Tween for 10 minutes, and then endogenous biotin and
streptavidin were blocked, respectively. Cells were then incubated with
TNB blocking serum (PerkinElmer) for 1 hour and thenwith the appropriate
primary antibodies (see Primary Antibodies section) overnight at 48C. Cells
were washed, incubated with the appropriate secondary biotinylated anti-
body (see Secondary Antibodies section) for 1 hour and then washed and
incubated for 30 minutes with streptavidin-Cy3 fluorophore. Finally, cells
werewashed inmountingmediumwith DAPI to stain nuclei. Cell immuno-
fluorescencewasanalyzedusingandINCellAnalyzer1000 (GEhealthcare).
The 96-well plate was positioned on the stage, and a 20x lens was used to
acquire immunofluorescent images of 200 cells per well using 3 different
filters: DAPI 360 nm excitation and 480 nm emission; GFP 480 nm and
510 nm, respectively; and Cy3 580 nm and 640 nm, respectively.
Primary Antibodies
The followingprimaryantibodieswereused foradhesionmoleculeor ligand
detection: anti-L-selectin antibody (1:50; Santa Cruz Biotechnology);
anti-VCAM-1 antibody (1:250; Millipore); anti-integrin a4 (1:250; Santa
Cruz Biotechnology); anti-ALCAM antibody (1:1000; R&D Systems);
anti-ICAM-1 antibody (1:1000; R&D Systems); anti-E-selectin antibody
(1:50; R&D Systems); anti-P-selectin antibody (1:50; BD Biosciences);
anti-VLA-4 antibody (1:100; Abcam); anti-integrin b4 (1:300; Santa Cruz
Biotechnology); anti-PSGL-1 (1:100; Santa Cruz Biotechnology);
anti-LFA-1 antibody (1:200; Abcam), and anti-VAP1 antibody (1:100;
Abcam). For colocalization studies, anti-GFAP antibody (1:400; Dako) was
used for astrocyte detection, anti-Iba-1 (1:400; Wako Chemicals) was
used for microglial detection, and anti-vWF (1:200; Millipore) antibodies
were used to identify endothelial cells. Tumor cells were detected by
virtue of their GFP tag.
Secondary Antibodies
The following secondary antibodies were used as appropriate: Cy3-
streptavidin conjugate (1:200;Invitrogen); anti-rabbit AMCA-conjugated
(1:100; Vector Laboratories); biotinylated polyclonal antibody to chicken
raised in rabbit (Abcam); biotinylated polyclonal antibody to goat raised
in horse (Vector Laboratories); polyclonal antibody to rat raised in rabbit
(Vector Laboratories); and biotinylated polyclonal to rabbit raised in goat
(Vector Laboratories).
Neutralizing Antibody Study
To block specific tumor-expressed ligands, MDA231BR-GFP cells were incu-
bated with different concentrations (50 or 100 mg/mL) of anti-ALCAM or
anti-a4 antibodies for either 1 or 2 hours to determine maximum neutral-
ization efficiency. In the case of VLA-4 neutralization, owing to the hetero-
dimeric structure (composed of integrins a4 and b1), blockade of the a4
chain provided selective inhibition of the whole protein. In order to ascer-
tain optimal blocking efficiency, ALCAM and VLA-4 expression was quanti-
fied via immunofluorescence in at least 300 cells per treatment group.
For subsequent in vivo experiments, MDA231BR-GFP cells were incu-
bated for 2 hours with either anti-ALCAM or anti-a4 neutralising antibodies
at 100 mg/mL (R&D system), based on the results of the dose-response
experiments, prior to intracardiac injection in female SCID mice as above
(n¼ 5/group). In addition, a mouse IgG1 isotype control antibody was
used to assess the effect of a non-anti-CAM antibody on metastatic
burden. To this end, a third set of MDA231BR-GFP cells was incubated
with this isotype-control (Cell Signaling Technology). under the same
conditions as the neutralizing antibodies. and subsequently injected intra-
cardially into SCID mice as above (n¼ 5). Brains were collected at day 21,
and the number of metastatic colonies was counted. Female SCID mice
(n¼ 5) injected with naive MDA231BR-GFP cells (1×105cells/100 mL PBS)
were used as the control group.
Assessment of Metastasis Morphology Following
CAM Blockade
In general, 3 different tumor colony morphologies were found in animals
injected with either naive MDA231BR-GFP cells or incubatedwith neutraliz-
ing antibody prior to intracardiac injection: (i) primarily perivascular,
co-optive growth along local vessels; (ii) small perivascular colonies with
minimal co-optive growth; and (iii) larger colonies showing parenchymal
invasion with or without co-optive growth (See Fig. 5). With regards to the
co-optive growth pattern, the degree of co-option was quantified as the
number of vessels that were encompassed (co-opted) by a single tumor.
Ineachcase, thepercentageofall tumors fallingwithineachmorphological
category was calculated.
Cell Viability Assay
To assess the effect of CAM neutralization onMDA231BR-GFP cells, prolifer-
ation and viability were measured using an MTT (3-[4,5-dimethylthiazol-
2-yl]-2,5 diphenyl tetrazolium bromide) assay. Cells were coated onto a
96-well plate and incubated with SCID mouse plasma for either 6 or
24 hours prior to and after incubation with neutralizing antibodies (50
and 100 mg/mL). After that, 50 mL of 5 mg/mL MTT was added to each
well, and the plates were incubated for 4 hours at 37 8C in 5% CO2. Media
were then removed and replacedwith 75 mL dimethyl sulfoxide to dissolve
insoluble purple formazan dye crystals. Absorbance was measured by a
photometric microplate reader (Tecan) at 570 nmwithin 30 minutes.
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Statistics
Statistical analysis was performed using Prism (GraphPad Software Inc.).
For the IHC quantitation, analysis of variance (ANOVA) was used to identify
overall significant differences between the different time points, followed
by pairwise unpaired t tests with Welch’s correction for unequal variances
to identify specific differences between the groups. To analyze differences
between groups treated with different concentrations of neutralizing anti-
bodies and control groups, average number of colonies, volume, and
number of vessels co-opted by individual tumors were compared by
ANOVA followed by post hoc Dunnett’s t tests. All data are expressed as
mean+standard error of the mean (SEM).
Results
Awell-establishedmetastaticmodel, induced via the hematogen-
ous route, was employed to allow evaluation of the seeding stage
of brain metastasis. Two different mammary carcinoma cell lines
were used (the mouse 4T1-GFP line and the less-aggressive
human MDA231BR-GFP line) to assess conservation of adhesion
molecule expression. No clinical signs were evident in any of the
groups.
CAM Expression in Brain Metastasis Models
Expressionof the12differentCAMs/ligandswasfirstquantifiedasa
percentage of the tumor area. For this purpose, tumor area was
defined as not only the area covered by tumor cells but also by
the glial, endothelial, or different immune cells contained within
the clearly circumscribed tumor border. This is because the
nature of metastatic colonies was heterogeneous and included
several specific host cell populations.
ALCAM, ICAM-1 and VCAM-1 all showed upregulation in both
models, with ALCAM showing the highest level of expression
(97% and 88% tumor area; Fig. 1) and VCAM-1 the lowest
(15%–20% tumor area; Fig. 1). VLA-4 (and subunit a4) and
LFA-1, cognate ligands to VCAM-1 and ICAM-1, respectively, also
showed widespread expression throughout the tumor area in
both models (Fig. 1). The integrin b4 and the cell surface enzyme
VAP-1, both previously implicated in metastasis, were also evalu-
ated; integrin b4 showed extensive expression throughout the
tumor area (.80% tumor area; Fig. 1) in both models, while
VAP-1 showed minimal levels of expression (Fig. 1).
Of the 3 selectins, E-selectin showed the greatest spatial extent
of expression in the 4T1-GFP model (82% tumor area; Fig. 1B),
while L- and P-selectin expression were much more restricted
(8% and 6% tumor area, respectively). In the less aggressive
MDA231BR-GFPmodel, all 3 selectins showed similar and relatively
low levels of expression (maximum 20% tumor area). PSGL-1, a
primary ligand forall 3 selectins, showedonlymoderateexpression
in both models (16% tumor area; Fig. 1B).
Little ornoconstitutiveexpressionof anyof the12CAMsstudied
was found in normal naive brain (Supplementary data, Fig. S1, S2)
or in metastasis-bearing brains at sites distant to metastatic foci.
However, it should be noted that pan-striatal DAB staining is
evident when using the anti-ALCAM antibody in both naive and
metastasis-bearing brain, which is weaker and independent of
the dense cell-specific staining observed at tumor sites.
Endothelial Colocalization of CAMs within the Brain
Vasculature
To identify CAMs that could play a role specifically in tumor cell
arrest and extravasation, their colocalization with the endothelial
marker,von Willebrand Factor (vWF) was assessed. VCAM,
ALCAM, and ICAM-1 all showed colocalization with the vascular
endothelium, as did VLA-4 (Fig. 2). In contrast, LFA-1, the ligand
to ICAM-1, was not found on the endothelial layer. Although
expressionof the integrinb4was found tocolocalizewith theendo-
thelium, this tended not to be at points of contact between the
metastatic colonies and brain vessels. Similarly, VAP-1 also coloca-
lized with the endothelium, but did so predominantly on vessels
surrounding the tumor colonies. All 3 selectins showed clear colo-
calization with tumor vessel endothelial cells (see Table 1, Fig. 2),
while their ligand, PSGL-1, did not (Fig. 2). Variable expression of
all 12 adhesion molecules was also evident on either astrocytes
or microglia, or both (Supplementary data, Figs. S3 and S4).
Expression of the 6 CAMs showing significant levels of expres-
sion at day 10 and colocalization with endothelial cell markers
was further assessed at day 5 after intracardiac injection of
4T1-GFP cells. VCAM-1 expression was notably higher at day 5
than day 10 (P, .005; Fig. 1B), while ICAM-1 expression was com-
parable at both time points (Fig. 1B). E-selectin, VLA-4, b4, and
ALCAM showed slight but significant (P, .005) lower levels of
expression at day 5 than day 10, although expression was still
marked (Fig. 1B).
Expression of CAMs on Tumor Cells
Having established the endothelial profile of CAM expression, we
subsequently determined their expression on the tumor cells
themselves, both in vitro and in vivo. All of the CAMs and their
ligands, except L-selectin, P-selectin, and VAP-1, were expressed
on the tumor cells both in vitro under all conditions and in vivo
(Table 1; Fig. 3, Supplementary data, S5 and S6). The CAMs
showing the highest levels of expression in the in vitro study were
ALCAM, VLA-4, a4 (subunit of VLA-4), b4, and E-selectin, and
thesemoleculeswerehighlyactivatedunderanyof the invitro con-
ditions (Figs. 3, Supplementary data, S5 and S6). Similarly, all of
these molecules showed clear expression on tumor cells in vivo.
Antibody Treatment Optimization
From the above experiments, we identified 2 CAMs (ALCAM and
VCAM-1) that are strongly upregulated early in metastasis devel-
opment on the endothelium and 2 CAMs (ALCAM and VLA-4) for
which the natural ligands are also strongly expressed on themeta-
static tumorcells. Thesefindings ledus tohypothesize thatALCAM/
ALCAM and VCAM-1/VLA-4 interactions may play a functional role
in the initial steps of metastasis seeding to the brain. To test this
hypothesis, either ALCAM or VLA-4 (a4b1) on the surface of
MDA231BR-GFP cells was blocked by incubation with neutralizing
antibodies to prevent binding to their target adhesion molecules
on the vascularendothelium.Owing toa lackof specificVLA-4neu-
tralizing antibody, an anti-a4 antibody was used, based on our
observations that a4 expression did not exceed that of VLA-4,
and was thus unlikely to reflect expression of other integrins
containing this subunit.
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Fig. 1. Expression of cellular adhesionmolecules. (A) Immunohistochemical detection of cell adhesionmolecules atmetastatic foci in BALB/c (4T1(D10))
and SCID (MDA(D21))mice injected intracardially with 1×105 4T1-GFPor MDA231BR-GFP cells, respectively, in 100ml PBS. Images are shown for day 10 in
the 4T1-GFPmodel and day 21 in theMDA231BR-GFPmodel. Scale bar 50 mm. (B) Graphs showing quantitative analysis of the expression of cell adhesion
moleculeswithin the tumorarea inBALB/c (days5and10)andSCIDmice (day21) injected intracardiallywith1×1054T1-GFP (4T1)orMDA231BR-GFPcells
(MDA), respectively, in 100 mLPBS. Resultsareexpressedas thepercentageareaof biomarkerexpressioncomparedwith the total tumorarea foreach time
point. Statistical significances are compared with the 4T1-GFP model day 5(a) and day 10(b); (P, .05–0.001. n¼ 4/time point).
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Fig. 2. Colocalization of adhesionmoleculeswith endothelial cells. Triple-color fluorescence images showing colocalization (arrows) between tumor cells
and endothelialmarker vonWillebrand Factor (vWF) in the 4T1-GFPmodel. All tumorcells injectedwereGFP positive, and therefore the greenfluorescence
corresponds to tumor cells. An AMCA fluorophore was used to localize the endothelial markers, and hence the blue color reflects vWF. To detect the 12
cellular adhesion molecules, a Cy3 fluorophore was used (red). Scale bar 50 mm. High magnification insets show regions of colocalization (indicated by
arrows).
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In the first instance, efficiency of CAM neutralization on
MDA231BR-GFP cells was measured by immunofluorescence and
found to be significantly reduced in both anti-ALCAM and anti-a4
treated cells at 50 and 100 mg/mL antibody concentrations (P,
.0001; Fig. 4A and B, Supplementary data, S7). However, following
incubation with 50 mg/mL of anti-ALCAM antibody, subsequent
incubation in mouse plasma for 6 hours increased the levels of
ALCAM immunofluorescence, indicating increased CAMexpression
on exposure to plasma. In contrast, following incubation with
100 mg/mL antibodies, no change in the level of neutralization
was observed on subsequent incubation with plasma up to
24 hours for either adhesion molecule (Supplementary data,
Fig. S7).
Viability and proliferation of MDA231BR-GFP cells treated with
neutralizing antibodies, as determined by MTT assay, was not
significantly different from that of untreated cells, either before
or after incubation with plasma (Fig. 4C and D). Interestingly,
however, control untreated cells incubated with plasma for either
6 or 24 hours showed a significant increase in cell viability, which
was blocked by preincubation with neutralizing antibodies
(Fig. 4C and D).
Metastatic Burden after Antibody-neutralization
of Tumor Cells
Once the most efficient dosing regime for antibody neutralization
had been established, their role in vivo was determined. Thus,
SCIDmice injected intracardially with either anti-a4 or anti-ALCAM
antibody-treatedMDA231BR-GFPcells showeda significant reduc-
tion in the number of tumor colonies in the brain at day 21 (63%
and 68%, respectively; P, .05; Fig. 5A). The total volume of
tumor burden was also significantly reduced in the anti-ALCAM-
treatedgroup (73%reduction; Fig.5A).Althoughamodest reduc-
tion in total tumor volume was apparent in the VLA-4 blocked
group (25%; Fig. 5A), this was not significant compared with
controls.While the control group exhibited a predominantly spher-
ical colony phenotype (70% colonies; Fig. 5B and C), assessment
of tumor colony shape and degree of either intravascular or peri-
vascular co-optive growth indicated that the anti-ALCAM and
anti-a4-treated animals showed more marked vessel co-option
and had the appearance of earlier stage colonies than the
control group, with some appearing to still be intravascular
(Fig. 5B and C). No significant differences were found between
the control group and animals injected with isotype-treated cells
(Fig. 5A) for any of the analyses.
Discussion
It is clear that communication between tumor cells and their host
environment is essential for both initiation and progression of
metastatic colonization in the brain. Yet our understanding of
these tumor-host interactions is far from complete. In particular,
our knowledge of the role of adhesion molecules in tumor cell
arrest and extravasation is poor, and the atypical inflammatory
response of the brain makes it difficult to extrapolate from other
metastatic sites in the body. Here we have demonstrated, using
in vivo models, that a subset of adhesion molecules (E-selectin,
VCAM-1, ALCAM, ICAM-1, VLA-4, and a4) are upregulated on the
cerebral endothelium soon after metastatic cell injection into the
circulation. At the same time, the natural ligands to these mole-
cules (PSGL-1, VLA-4, ALCAM, LFA-1, and VCAM-1) are highly
expressed on the tumor cells themselves. Furthermore, we have
demonstrated that blocking 2 of the most strongly upregulated
CAMs on the tumor cells (ALCAM and VLA-4) significantly
decreased the number of metastatic colonies forming within the
brain. Taken together, these findings suggest a key role for this
subset of adhesion molecules in the early stages of tumor cell
arrest and/or extravasation.
Table 1. Summary of biomarker colocalization with endothelial cells, astrocytes, microglia, and tumor cells in the 4T1-GFP model
% Expression Endothelium Astrocytes Microglia Tumor Cells
In vivo In vitro + plasma +CXCL12
VCAM-1 13.7+15.8 + + + + + + +
VLA-4 33.5+9.7 + +/2 + + ++ ++ ++
a4 46.6+9.4 + + + + ++ ++ ++
b4 80.3+7.5 + +/2 +/2 + ++ ++ ++
ALCAM 97. 1+3.6 + 2 + + ++ ++ ++
ICAM-1 44.5+7.7 + + + + + + +
LFA-1 33.2+10.4 2 + + + + + ++
VAP-1 3.8+1.5 + + + 2 2 2 2
E-selectin 82.7+5.7 + + + + ++ ++ ++
L-selectin 8.2+6.6 + + + 2 2 + 2
P-selectin 5. 7+7.6 + + + 2 2 2 2
PSGL-1 16.8+13.2 2 + + + + ++ +
The first column shows the highest level of expression (mean+SEM) for each adhesionmolecule. The remaining columns indicate colocalization of each
adhesionmoleculewith endothelium (vWF), astrocytes (GFAP),microglia (Iba-1), and tumor cells (GFP). Someof themarkers appeared closely associated
with cellular markers, but it was not possible to determinewhether they colocalized or were on a separate but closely apposed cell; in those cases+/2 is
used. For the in vitro study, - denotes negative expression;+ 10%–50% cells positive;++.50% cells positive.
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Functional Role of VLA-4/VCAM-1 in Brain Metastasis
Previous studies in other tissue beds suggest that tumor cells
undergo the same succession of steps as extravasating leukocytes
(ie, rolling, adhesion, and transmigration [diapedesis]), and utilize
similar cell adhesion molecules.16 Integrins are a key family of
transmembrane adhesion receptors that are composed of non-
covalently linked a and b subunits and have been shown to be
involved in adhesion of leukocytes to the vascular endothelium.16
Similarly, the high affinity interactions between VLA-4 (a4b1) and
VCAM-1have been shown to promote transmigrationofmetastat-
ic melanoma cells across activated human endothelial layers in
vitro17 and differential expression of VLA-4 found on metastatic
versus nonmetastatic tumor cell lines. These data have been
taken to suggest that VLA-4 is important inmetastatic progression
to the liver and lungs.18
To date, however, little was known of VLA-4 involvement in
metastasis seeding to the brain, although blockade of VCAM-1 on
culturedbrainendothelial cellshasbeenshownto reduceadhesion
of metastatic Lewis lung carcinoma cells.19 In the current study,
each of our cell lines showed marked expression of both VLA-4
anda4 (subcomponentofVLA-4)both invitroand invivo.Moreover
VCAM-1, the receptor for VLA-4, was widely expressed on the
endothelium from as early as day 5 after intracardiac induction,
aswehavepreviously demonstrated.Moreover, our in vivo findings
demonstrated a significant reduction inmetastasis seeding to the
brain followinga4 blockadeonMDA231BR-GFPcells. Thesefindings
support the concept that VLA-4/VCAM-1 interactions are involved
in tumor cell arrest and subsequent extravasation across the
brain endothelium.
Functional Role of ALCAM in Brain Metastasis
ALCAM is a transmembrane glycoprotein that is upregulated on
activated T cells and monocytes and mediates both heterophilic
ALCAM-CD6 and homophilic ALCAM-ALCAM interactions. Recent
work has also shown upregulation of ALCAM on endothelial cells
in response to inflammatory stimuli, albeit primarily in vitro.20,21
In the current study, ALCAM was highly expressed on tumor cells,
both in vitro and in vivo, and also on tumor-associated endothe-
lium. In contrast, expression of VAP-1, another transmembrane
Fig. 3. In vitro expression of cellular adhesion molecules on metastatic tumor cells. Negative controls are shown for unbiased comparison with the
plasma-treated, cytokine-treated, and naive groups for 2 of the most highly expressed adhesion molecules, ALCAM and VLA-4. Cells were coated onto
96-well plates and after 48 hours of growth were incubated for 6 hours with 200 mL of plasma (55%) in DMEM. Red fluorophore (Cy3) for each marker.
Scale bar 100 mm. (Data for tumor cell expression of the other 10 CAMs are shown in Supplementary data, Figs. S5 and S6).
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glycoprotein that supports rolling, firm adhesion, and transmigra-
tion of leukocytes, was for the most part negligible on both endo-
thelium and tumor cells. Notably, following ALCAM blockade on
MDA231BR-GFP cells, a reduced number of tumor colonies were
found within the brain parenchyma, and a change in metastasis
morphology was apparent with a substantial proportion of
colonies appearing to remain intra- or perivascular. Our results
suggest both a reduction in the adherence of tumor cells to the
endothelium and a slowing of the extravasation process following
ALCAM blockade. These in vivo findings concur with very recent
work suggesting that ALCAM may play a role in both breast
cancer metastasis22,23 and melanoma metastasis to the lung.24
It has also been suggested that ALCAM expression on metastatic
tumor cells may facilitate aggregation and binding to circulating
monocytes through ALCAM-CD6 interactions, which enables the
metastatic cells to circumvent immune surveillance and aids
their extravasation across the endothelium.25 Thus, neutralization
of ALCAM prior to introduction into the bloodstream may reduce
aggregation and binding to activated leukocytes, both enhancing
immune clearance and inhibiting extravasation across the
endothelium. Taken together, the above findings strongly
suggest that ALCAM plays an important functional role in early
tumor cell adhesion in brain metastasis.
Potential Role for ICAM-1 and E-selectin
in Metastasis Seeding
Owing to its presence onmanycancer cell types26 and its potential
role inmetastasis,27 it has been suggested that ICAM-1 expression
may serve as a useful biomarker for tumor prognosis and progres-
sion. Marked upregulation of ICAM-1 was evident on the vascular
endothelium in both models studied here and showed extensive
expression extending beyond tumor margins at later time points.
At the same time, expression of its cognate ligand LFA-1 was
notably absent from the endothelium but highly upregulated on
tumor cells both in vitro and in vivo. Upregulation of ICAM-1 was
evident from as early as day 5 in the 4T1-GFP model; although
LFA-1 expression on tumor cells was not as marked as VLA-4 and
ALCAM, the contribution of LFA-1/ICAM-1 to tumor cell adhesion/
extravasation is a focus for subsequent investigation.
Fig. 4. Optimization of antibody blockade. (A) Confocal images of the expression of ALCAM and VLA-4 on MDA231BR-GFP cells under control conditions
after 2 hours antibody incubation (100 mg/mL) with the corresponding neutralizing antibody and after the addition of plasma. Red dye (Cy3) for each
marker. Scale bar 100 mm. (B) Percentage of cells showing positive ALCAM and VLA-4 expression under 3 different conditions. Statistical significances
were compared with control groups (P, .0001). (C) MTT assay showing the viability of the cells under normal medium (100% DMEM) conditions (6hD
or 24hD), 55% DMEM (6 h Dd or 24 h Dd 6-hour or 24-hour exposure to plasma (6hP or 24hP), 2 hours of incubation with the anti-a4 (VLA-4, 2 h Ab)
followed by 6-hour or 24-hour exposure to mouse plasma (2hAb+ 6hP or 24hP). D. As for C, but with anti-ALCAM neutralizing antibody. Percentages
are expressed with respect to normal medium conditions groups. Statistical significances are compared with control 6h-24hD (P, .05).
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Fig. 5. Metastatic burden after intracardiac injection of antibody-blocked MDA231BR-GFP cells. (A) Graphs showing number of metastatic colonies and
tumor volume per mm3 of brain tissue after antibody treatment of MDA231BR-GFP cells (100 mg/mL anti-a4 or anti-ALCAM or isotype IgG control)
compared with untreated tumor cells (n¼ 5/group). Tumors were also assessed according to the degree of co-option (number of vessels conforming a
single colony). * Denotes statistical significance versus control group (* P, .05, ** P, .01, *** P, .001). # Denotes statistical significance versus isotype
control group (# P, .05, ## P, .01). a4 and ALCAM groups were also significantly different in the degree of co-option and the volume of tumor burden.
(B) Images illustrating the 3 main morphological phenotypes of tumor colonies observed within the brain and the percentage of all tumors in each
group exhibiting each type of growth. (C) Confocal images illustrating the more perivascular/co-optive growth in the antibody-blocked groups (anti-a4
and anti-ALCAM) compared with animals injected with the non-treated MDA231BR-GFP cells (Control). Scale bars 150 mm.
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Studies in other organs such as lung and liver have demon-
strated that interactions between selectins and their ligands
mediate tethering and rolling of tumor cells along the vascular
endothelium,28,29 and the degree of selectin ligand expression on
cancer cells correlates closely with metastatic progression.30
Expression of all 3 selectins was evident on endothelial cells in
the current studybutwithdifferential temporal and spatial expres-
sion profiles. Notably, expression of E-selectin was one of the
highest measured in our brain metastatic model. However,
several functional ligands exist for this glycoprotein (PSGL-1,
ESL-1, and CD4430), and consequently blockade of ligands to
E-selectin on tumor cells is not straightforward. Nevertheless, the
role of E-selectin in metastasis seeding to the brain will be an
important target for future studies.
In conclusion, we have determined the temporal, spatial, and
cellular expression profiles of a spectrum of CAMs during the
early stages of metastasis seeding in the brain. Unlike previous
studies inwhichonlysinglemoleculesor small groupsofmolecules
have been studied, here a broad range of molecules were consid-
ered with the view that no single adhesion molecule can be
solely responsible for any of these processes. Rather, it is likely
that these interactions are mediated by a number of structurally
diverse cell surface receptors and their ligands/counter-receptors.
Our findings suggest that certain CAM/ligand interactions are im-
portant in tumor cell adhesion and extravasation. In particular,
VCAM-1/VLA-4, and ALCAM/ALCAM appear to play an important
functional role inmetastasis seeding, while ICAM-1/LFA-1 interac-
tions and the role of endothelial E-selectin expression alsowarrant
further investigation. Importantly, theseearlymarkersofmetasta-
sis seeding may yield new diagnostic targets, as demonstrated in
our recent work with a VCAM-1-targeted molecular MRI contrast
agent,14 as well as new therapeutic targets for brain metastasis.
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